Abstracts tagged "Biomarkers"

Abstract Number: 0244 • ACR Convergence 2022
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
Yicong Li¹, Chun Wu², Michael Maldonado², Peter Schafer², S. Louis Bridges, Jr.³, William Rigby⁴, Vivian Bykerk³, Jane Buckner⁵ and Jinqi Liu², ¹Parexel International, Durham, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Hospital for Special Surgery, New York, NY, ⁴Dartmouth Hitchcock Medical Center, Lebanon, PA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular…
Abstract Number: 0479 • ACR Convergence 2022
A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA
Colm Kirby¹, Rachael Flood¹, Ronan Mullan¹, Grainne Murphy² and David Kane¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Cork University Hospital, Cork, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) has become a reliable alternative to biopsy for diagnosing GCA. However, normalisation of pathologic findings have been…
Abstract Number: 0636 • ACR Convergence 2022
Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions
Background/Purpose: There is a pressing need to identify novel therapeutic approaches and noninvasive biomarkers in lupus nephritis (LN). In this study, we quantified serum soluble…
Abstract Number: 0884 • ACR Convergence 2022
Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis
Margaret Ma¹, Fowzia Ibrahim², David Scott² and Andrew Cope³, ¹National University Hospital, Singapore, Singapore, ²King's College London, London, United Kingdom, ³King's College London, Surrey, United Kingdom
Background/Purpose: Reliable objective assessment of remission is important for the optimal management of rheumatoid arthritis (RA) patients. Calprotectin is a heterocomplex of the S100 proteins…
Abstract Number: 1135 • ACR Convergence 2022
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, Anna Broder², Daming Shao³, Vartika Kesarwani⁴, Brianna Lally⁵, Masako Suzuki⁶, J. Michelle Kahlenberg⁷, Jennifer Aguilan⁶ and Simone Sidoli⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Hackensack University Medical Center, Hackensack, NJ, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴University of Connecticut, Farmington, CT, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
Abstract Number: 1416 • ACR Convergence 2022
Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Roxana Coras¹, Mona Alotaibi², Dimitrios Pappas³, Joel Kremer⁴, Jeffrey Curtis⁵, Arthur Kavanaugh⁶, Ted Mikuls⁷, Geoffrey Thiele⁸, mohit jain² and Monica Guma⁹, ¹University of California San Diego, San Diego, CA, ²Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶University of California San Diego, La Jolla, CA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹UCSD, La Jolla, CA
Background/Purpose: Bioactive lipids comprise distinct classes of bioactive molecules with functions that are critical for joint disease, including regulation of not only inflammation but also…
Abstract Number: 1585 • ACR Convergence 2022
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Jeffrey Curtis¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹University of Alabama at Birmingham, Hoover, AL, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or…
Abstract Number: 1859 • ACR Convergence 2022
Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
Jun Nakamura, Takao Nagashima and Kojiro Sato, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: Interstitial Lung Disease (ILD) accompanied with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is usually rapidly progressive and life-threatening with poor prognosis. Although…
Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Sofie Falkenløve Madsen¹, Dovile Sinkeviciute², Christian Thudium², Morten Karsdal² and Anne-Christine Bay-Jensen², ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
Abstract Number: 2214 • ACR Convergence 2022
Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)
Christopher Redmond¹, Moses Kitakule², Riccardo Castagnoli³, Francesco Licciardi⁴, Cihan Oguz⁵, Maria Cecilia Poli⁶, Aran Son⁵, Sarah Weber⁵, Luigi Notarangelo⁷, Helen Su⁸ and Daniella Schwartz⁹, ¹National Institutes of Health, Rockville, MD, ²Columbia University, New York, NY, ³National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁴OSPEDALE REGINA MARGHERITA, Torino, Italy, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶Roberto del Rio, Santiago, Chile, ⁷NIAID/NIH, Bethesda, MD, ⁸NIH/NIAID, Bethesda, MD, ⁹National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable…
Abstract Number: 0248 • ACR Convergence 2022
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
Veronica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo¹, Víctor M. Mora-Cuesta¹, David Iturbe-Fernández¹, Leticia Lera-Gómez¹, Diana Prieto-Peña¹, Virgi Portilla¹, Ricardo Blanco², Alfonso Corrales¹, Oreste Gualillo³, José M. Cifrián¹, Raquel Lopez Mejias⁴ and Miguel Ángel González-Gay⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁴IDIVAL, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
Abstract Number: 0491 • ACR Convergence 2022
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Despina Michailidou¹, Bhargavi Duvvuri¹, Runa Kuley¹, David Cuthbertson², Peter Grayson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Antoine Sreih⁷, Kenneth J. Warrington¹¹, Tomas Mustelin¹, Paul Monach¹², Peter Merkel¹³ and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²VA Boston Healthcare System, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…
Abstract Number: 0643 • ACR Convergence 2022
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Mary Horton¹, Joanne Nitithalm², Kimberly Taylor³, Laura Trupin⁴, Patricia Katz⁵, Jinoos Yazdany⁶, Maria Dall'Era⁷, Lisa Barcellos⁸, Lindsey Criswell⁹ and Cristina M Lanata¹⁰, ¹NIH/NHGRI, Oakland, CA, ²NIH/NHGRI, Bethesda, MD, ³University of Californi, San Francisco, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶UCSF, San Francisco, CA, ⁷University of California, Division of Rheumatology, San Francisco, CA, ⁸School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, ⁹National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁰NIH/NHGRI, Washington, DC
Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The…
Abstract Number: 0889 • ACR Convergence 2022
Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
Joshua Baker¹, Katherine Wysham², Bryant England³, Punyasha Roul⁴, Aleksander Lenert⁵, Grant Cannon⁶, Brian Sauer⁷, Geoffrey Thiele³ and Ted Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Puget Sound/University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵University of Iowa, Iowa City, IA, ⁶Retired, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Adipokines are fat and muscle-secreted protein hormones that regulate metabolism. Adiponectin has been associated with fracture in the general population while the role of…
Abstract Number: 1144 • ACR Convergence 2022
Circulating miRNAs and Difficult-To-Treat Rheumatoid Arthritis: The Screening Study
Jiří Baloun¹, Aneta Pekčcová², Heřman Mann³, Jiří Vencovský⁴, Karel Pavelka⁵ and Ladislav Šenolt⁴, ¹Institue of Rheumatology, Prague, Czech Republic, ²Institue of Rheumatology, Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic
Background/Purpose: Biologic (b-) and targeted synthetic (ts-) disease-modifying antirheumatic drugs (DMARDs) have brought significant progress in the treatment of rheumatoid arthritis (RA), but a significant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].